A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases

Raeber et al. (Fri,) studied this question.

www.synapsesocial.com/papers/69d7cb9533ca018b39ae2dd3 — DOI: https://doi.org/10.1016/j.ebiom.2023.104539

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease· 2011 · 1,113 citations
2. Amg 592 Is an Investigational IL-2 Mutein That Induces Highly Selective Expansion of Regulatory T Cells· 2017 · 22 citations
3. Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2· 1998 · 485 citations
4. Engineering IL-2 for immunotherapy of autoimmunity and cancer· 2022 · 345 citations
5. An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer· 2020 · 70 citations